Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Titel:
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Auteur:
Gregorc, Vanesa Novello, Silvia Lazzari, Chiara Barni, Sandro Aieta, Michele Mencoboni, Manlio Grossi, Francesco Pas, Tommaso De de Marinis, Filippo Bearz, Alessandra Floriani, Irene Torri, Valter Bulotta, Alessandra Cattaneo, Angela Grigorieva, Julia Tsypin, Maxim Roder, Joanna Doglioni, Claudio Levra, Matteo Giaj Petrelli, Fausto Foti, Silvia ViganĂ², Mariagrazia Bachi, Angela Roder, Heinrich